1887
  1. Home
  2. A-Z Publications
  3. Journal of Emergency Medicine, Trauma and Acute Care
  4. Volume 2024, Issue 6
  5. Article
6 - Al-Bayan University Scientific Conference
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Solid oral dosage forms are widely used in the management of chronic diseases. They are preferred due to their ease of administration, affordability, stability, and accuracy in dose measurement. However, there are challenges with oral delivery due to a number of physiological and metabolic barriers that may impair therapeutic efficacy. Difficulties such as limited water solubility and biological membrane translocation can have a major impact on how well a drug is absorbed. The complexity of developing an oral dosage form is further compounded by considerations such as the drug stability, the impact of gastrointestinal pH, and interactions with metabolic enzymes and biological efflux mechanisms. One of the most important pharmacokinetic indicators of a drug's ability to achieve systemic availability after absorption is bioavailability. It is controlled by how well the drug dissolves and how well it passes through physiological barriers. The purpose of bilosomes, vesicular carriers composed of bile salts and nonionic surfactants, is to improve the administration of vaccinations and drugs. The gastrointestinal tract (GIT) can efficiently transport a range of pharmacological drugs, such as those with antibacterial, antifungal, and antiparasitic capabilities, as well as vaccines and bioactive molecules that target infectious organisms, due to their stability and malleability. For oral medications, bilosomal formulations exhibit higher delivery efficacy due to the complex and hostile environment of the GIT. This research evaluates the potential of bilosomes as a delivery system and highlights how they could be used to administer medications for diseases and viruses that affect the GIT.

© 2024 Salman, Alhammid, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2024.absc.17
2024-10-14
2024-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2024/6/jemtac.2024.absc.17.html?itemId=/content/journals/10.5339/jemtac.2024.absc.17&mimeType=html&fmt=ahah

References

  1. Zarenezhad E, Marzi M, Abdulabbas HT, Jasim SA, Kouhpayeh SA, Barbaresi S, et al. Bilosomes as Nanocarriers for the drug and vaccine delivery against gastrointestinal infections: Opportunities and challenges. J Funct Biomater. 2023 Sep 1;14(9):453. doi: 10.3390/jfb14090453.
     [Google Scholar]
  2. Nemati M, Fathi-Azarbayjani A, Al-Salami H, Roshani Asl E, Rasmi Y. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics. Cell Biochem Funct. 2022 Aug;40(6):623–35. doi: 10.1002/cbf.3732.
     [Google Scholar]
  3. Saifi Z, Rizwanullah M, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol. 2020 Jun;57:101634. doi: 10.1016/j.jddst.2020.101634.
     [Google Scholar]
  4. Kulkarni S, Prabhakar B, Shende P. Stabilization of lipid vesicles: Upcoming strategic insights for product development. J Mol Liquids. 2022;348(S1):118430. doi: 10.1016/j.molliq.2021.118430.
     [Google Scholar]
  5. Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: Superior vesicular carriers. Curr Drug Therapy. 2020;15(4):312–20. doi: 10.2174/1574885514666190917145510.
     [Google Scholar]
  6. Shukla A, Mishra V, Kesharwani P. Bilosomes in the context of oral immunization: Development, challenges and opportunities. Drug Discov Today. 2016 Jun;21(6):888–99. doi: 10.1016/j.drudis.2016.03.013.
     [Google Scholar]
  7. Elia RV, Woods S, Butcher W, McGahon J, Khadke S, Perrie Y, et al. Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments. J Control Release. 2019 Mar 28:298:202–12. doi: 10.1016/j.jconrel.2019.02.002.
     [Google Scholar]
  8. Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Yasir M, Ghoneim MM, et al. Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study. Drug Deliv. 2021 Dec;28(1):2562–2573. doi: 10.1080/10717544.2021.2008055.
     [Google Scholar]
  9. Zafar A, Alsaidan OA, Imam SS, Yasir M, Alharbi KS, Khalid M. Formulation and evaluation of moxifloxacin loaded bilosomes in-situ gel: Optimization to antibacterial evaluation. Gels. 2022 Jul 4;8(7):418. doi: 10.3390/gels8070418.
     [Google Scholar]
  10. Binsuwaidan R, Sultan AA, Negm WA, Attallah NGM, Alqahtani MJ, Hussein IA, et al. Bilosomes as nanoplatform for oral delivery and modulated in vivo antimicrobial activity of lycopene. Pharmaceuticals (Basel). 2022 Aug 24;15(9):1043. doi: 10.3390/ph15091043.
     [Google Scholar]
  11. Taher S, Ahmed Z, Al-Kinani K, Alwan Z. Solid lipid nanoparticles as a promising approach for delivery of anticancer agents: Review article. Mil Med Sci Lett (Voj Zdrav Listy). 2022;91(3):197–207. doi: 10.31482/mmsl.2021.042.
     [Google Scholar]
  12. Abdulqader A, Ayash N. Preparation and characterization of posaconazole as a nano-micelle using d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Iraqi J Pharm Sci. 2023;32:26–32. doi: 10.31351/vol32issSuppl.pp26-32.
     [Google Scholar]
  13. Niu M, Lu Y, Hovgaard L, Guan P, Tan Y, Lian R, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012 Jun;81(2):265–72. doi: 10.1016/j.ejpb.2012.02.009.
     [Google Scholar]
  14. Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2016 Jul;23(6):1847–67. doi: 10.3109/10717544.2014.976892.
     [Google Scholar]
  15. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208–19. doi: 10.1016/j.apsb.2011.09.002.
     [Google Scholar]
  16. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998 Oct;172(1–2):33–70. doi: 10.1016/S0378-5173(98)00169-0.
     [Google Scholar]
  17. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech. 2010;11(3):1119–27. doi: 10.1208/s12249-010-9480-2.
     [Google Scholar]
  18. Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal AM, et al. Bile salt stabilized vesicles (Bilosomes): A novel nano-pharmaceutical design for oral delivery of proteins and peptides. Curr Pharm Des. 2017;23(11):1575–88. doi: 10.2174/1381612823666170124111142.
     [Google Scholar]
  19. Muhesen RA, Ayash N. Formulation and characterization of olmesartan medoxomil as a nanoparticle. Res J Pharm Technol. 2023 Jul;16(7):1–7. doi: 10.52711/0974-360X.2023.00547.
     [Google Scholar]
  20. Nemr AA, El-Mahrouk GM, Badie HA. Hyaluronic acid-enriched bilosomes: An approach to enhance ocular delivery of agomelatine via D-optimal design: formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv. 2022 Dec;29(1):2343–56. doi: 10.1080/10717544.2022.2100513.
     [Google Scholar]
  21. Edhari GH, Al Gawhari FJ. Study the effect of formulation variables on preparation of nisoldipine loaded nano bilosomes. Pharm Sci. 2023;32:271–82. doi: 10.31351/vol32issSuppl.pp271-282.
     [Google Scholar]
  22. Wang C, Siriwardane DA, Jiang W, Mudalige T. Quantitative analysis of cholesterol oxidation products and desmosterol in parenteral liposomal pharmaceutical formulations. Int J Pharm. 2019 Oct 5:569:118576. doi: 10.1016/j.ijpharm.2019.118576.
     [Google Scholar]
  23. Smail SS, Ghareeb MM, Omer HK, Al-Kinani AA, Alany RG. Studies on surfactants, cosurfactants, and oils for prospective use in formulation of ketorolac tromethamine ophthalmic nanoemulsions. Pharmaceutics. 2021 Mar 30;13(4):467. doi: 10.3390/pharmaceutics13040467.
     [Google Scholar]
  24. Kauslya A, Borawake PD, Shinde JV, Chavan RS. Niosomes: A novel carrier drug delivery system. J Drug Deliv Ther. 2021 Jan–Feb;11(1):162–170. doi: 10.22270/jddt.v11i1.4479.
     [Google Scholar]
  25. Alruwaili NK, Zafar A, Alsaidan OA, Yasir M, Mostafa EM, Alnomasy SF, et al. Development of surface modified bilosomes for the oral delivery of quercetin: Optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study. Drug Deliv. 2022 Dec;29(1):3035–50. doi: 10.1080/10717544.2022.2122634.
     [Google Scholar]
  26. Dopazo GA, Martinez-Castillo C, Alonso-Ferrer M, Mejuto JC. Modeling the behavior of amphiphilic aqueous solutions. In: Mazzeo PL, Spagnolo P (eds.), Deep Learning Applications. IntechOpen; 2021.
     [Google Scholar]
  27. Waglewska E, Pucek-Kaczmarek A, Bazylińska U. Novel surface-modified bilosomes as functional and biocompatible nanocarriers of hybrid compounds. Nanomaterials (Basel). 2020 Dec 10;10(12):2472. doi: 10.3390/nano10122472.
     [Google Scholar]
  28. Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv. 2014 Mar;21(2):87–100. doi: 10.3109/10717544.2013.838077.
     [Google Scholar]
  29. Witika BA, Bassey KE, Demana PH, Siwe-Noundou X, Poka MS. Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications. Int J Mol Sci. 2022 Sep;23(17):9668. doi: 10.3390/ijms23179668.
     [Google Scholar]
  30. Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: In vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res. 2019 Mar;29(1):73–85. doi: 10.1080/08982104.2018.1430831.
     [Google Scholar]
  31. Naji GH, Al Gawhari FJ. Evaluation of types and concentration of bile salts impact on physical properties of nisoldipine-loaded bilosomes. Pharmacia. 2024;71:1–7. doi: 10.3897/pharmacia.71.e116917.
     [Google Scholar]
  32. Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: In vitro and ex vivo optimization. J Liposome Res. 2019 Jun;29(2):171–82. doi: 10.1080/08982104.2018.1524482.
     [Google Scholar]
  33. Xu W, Yu X, Liang R, Liu S, Tian Q, Deng R, et al. Generation of polymer nanocapsules via a membrane-extrusion emulsification approach. Mater Lett. 2012 Jun 15;77:96–9. doi: 10.1016/j.matlet.2012.03.004.
     [Google Scholar]
  34. Jana SS, Lad MD, Subramanian S. Bilosomes as non-invasive drug delivery system. Int J Creative Res Thoughts. 2022 Apr;10(4):d854–69.
     [Google Scholar]
  35. Elnaggar YSR. Multifaceted applications of bile salts in pharmacy: An emphasis on nanomedicine. Int J Nanomed. 2015 Jun 12;10:3955–71. doi: 10.2147/IJN.S82558.
     [Google Scholar]
  36. Zafar A, Alruwaili NK, Imam SS, Hadal Alotaibi N, Alharbi KS, Afzal M, et al. Bioactive apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment. Saudi Pharm J. 2021 Mar;29(3):269–79. doi: 10.1016/j.jsps.2021.02.003.
     [Google Scholar]
  37. Ali SK, Al-Akkam EJ. Effects of different types of bile salts on the physical properties of ropinirole-loaded. Bilosomes. Al-Rafidain J Med Sci. 2023;5:134–42. doi: 10.54133/ajms.v5i.176.
     [Google Scholar]
  38. Ali SK, Al-Akkam EJ. Bilosomes as soft nanovesicular carriers for ropinirole hydrochloride: Preparation and in-vitro characterization. Iraqi J Pharm Sci. 2023;32(Suppl.):177–87. doi: 10.31351/vol32issSuppl.pp177-187.
     [Google Scholar]
  39. Elkomy MH, Alruwaili NK, Elmowafy M, Shalaby K, Zafar A, Ahmad N, et al. Surface-modified bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics. 2022 Mar 3;14(3):563. doi: 10.3390/pharmaceutics14030563.
     [Google Scholar]
  40. Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: Improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. J Liposome Res. 2019 Sep;29(3):251–63. doi: 10.1080/08982104.2018.1551408
     [Google Scholar]
/content/journals/10.5339/jemtac.2024.absc.17
Loading
Bilosome as a potential carrier for improving poor oral drug bioavailability
Journal of Emergency Medicine, Trauma and Acute Care 2024, 17 (2024); https://doi.org/10.5339/jemtac.2024.absc.17
/content/journals/10.5339/jemtac.2024.absc.17
/content/journals/10.5339/jemtac.2024.absc.17
Loading

Data & Media loading...

Keyword(s): bilosomes, gastrointestinal tract and oral drug delivery

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error